In this episode, we’re joined by Claire Love, PwC’s global health industries advisory leader. We discuss PwC’s recent report showing the opportunities in the fertility and reproductive health market. The post MedCity FemFwd: Opportunities in the Fertility Market appeared first on MedCity News.

Health tech companies made several major funding announcements in September. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in September appeared first on MedCity News.

For one ICU physician and startup CMO, the more immediate danger isn’t an autonomous system taking over medicine and leaving human decision-making behind. It’s healthcare organizations harnessing AI primarily to increase efficiency while leaving healthcare providers even more mired in complexity and regulation. The post AI’s Healthcare ‘Doomsday’? It May Be Less About Autonomy Than Trust appeared first on MedCity News.

AI could play a meaningful role in advancing social care. Not by replacing people, but by helping them and organizations doing this work move faster, see patterns earlier, and coordinate more effectively.  The post AI Won’t Fix Social Care, But Could It Help Us Finally Make It Work? appeared first on MedCity News.

Tiny Health’s Series B round was led by B Capital, with participation from Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. The post Tiny Health Secures $33M to Expand Microbiome Testing appeared first on MedCity News.

Unite Us and Instacart announced Tuesday that they are partnering to connect healthcare organizations’ care coordination efforts with grocery benefits, with the aim of making food-as-medicine programs easier to launch and operate at scale. The post Unite Us, Instacart Link Care Coordination and Grocery Benefits to Scale Food-as-Medicine appeared first on MedCity News.

AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment. The post AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug appeared first on MedCity News.

In this episode of the MedCity Pivot Podcast, CEO Priya Abani talks about the evolution of AliveCor, one of the earliest digital health companies. The post MedCity Pivot Podcast: A Conversation With AliveCor’s Priya Abani appeared first on MedCity News.

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation The post The Illegal Drug Marketplace in Your Patients’ Pockets appeared first on MedCity News.

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections. The post DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens appeared first on MedCity News.

The Association for Direct Care launched a coalition focused on expanding direct contracting to lower healthcare costs. The post New Coalition Launches to Expand Direct Contracting appeared first on MedCity News.

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology. The post Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch appeared first on MedCity News.

While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment. The post Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care appeared first on MedCity News.

[Sponsored] Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats? The post Hospital and Payer AI Governance Is at a Crossroads appeared first on MedCity News.

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder appeared first on MedCity News.